Pharmacogenetics and Ecogenetics
Pharmacogenetics started in the mid-1950’s with the demonstration that two unrelated drug reactions were caused by different genetically determined biochemical aberrations: pseudocholinesterase variation as the cause of suxamethonium sensitivity and abnormalities in red cell glutathione metabolism as an explanation for primaquine sensitivity. Genetic differences in acetylation of INH were shown soon thereafter. Impressed by these developments, I pointed out the relevance of genetic variation in the elucidation of drug reactions and Vogel coined the term pharmacogenetics (see Motulsky, 1972, for references).
KeywordsNormal Distribution Curve Genetic Concept Potential Biologic Effect Drug Metabolism Study Level Assay
Unable to display preview. Download preview PDF.
- Dost, F. H.: Der Blutspiegel. Leipzig: Georg Thieme 1953Google Scholar
- Motulsky, A. G.: History and current status of pharmaco—genetics. In: Human genetics. Proceedings of the Fourth International Congress of Human Genetics, Paris, September 1971, pp. 381—390. Amsterdam: Excerpta Medica 1972Google Scholar
- Motulsky, A. G.: Ecogenetics: Genetic variation in susceptibility to environmental agents. In: Human genetics. Proceedings of the Fifth International Congress of Human Genetics, Mexico City, October 10—15, 1976, pp. 375—385. Amsterdam: Excerpta Medica 1977Google Scholar
- Omenn, G. S., Motulsky, A. G.: Psychopharmacogenetics. In: Human behavior genetics, A.R. Kaplan, ed., pp. 363—384. Springfield (111.): Charles C. Thomas 1976Google Scholar
- Omenn, G. S., Motulsky, A. G.: ‘Eco-genetics’: Genetic variation in susceptibility to environmental agents. In: Genetic Issues in Public Health and Medicine, B.H. Cohen, A.M. Lilienfeld, P.C. Huang, eds., pp. 83—111. Springfield (111.): Charles C. Thomas 1978Google Scholar